Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year over year. Globus anticipates $2.80 billion to $2.90 billion in sales after the closing of the purchase, with non-GAAP earnings per share ranging from $3.10 to $3.40.
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation. Globus Medical expects to report full financial results for 2024 and provide its updated financial outlook for 2025 during its scheduled earnings announcement on February 20, 2025.
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...
Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...
Learn more about whether Globus Medical, Inc. or Smith & Nephew plc is a better investment based on AAII's A+ Investor grades ...
BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, after the company preannounced Q4 revenue that was 3% above the Street ...
In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback